Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Imunon, Inc. IMNN

Healthcare  —  Biotechnology
1.41 0.06 4.44% as of 25 Sep
Market cap
$7.3M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Imunon, Inc. (IMNN) Business Profile

Updated before January 2025

Company Overview

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on the development of innovative therapies that harness the power of the immune system to treat cancer and infectious diseases. Founded in 2000 and headquartered in Lawrenceville, New Jersey, Imunon has established itself as a leader in the field of immunotherapy and gene-based medicine. The company was originally known as Celsion Corporation but rebranded to Imunon, Inc. in 2022 to better reflect its strategic focus on immunotherapy and its expanding pipeline of innovative treatments.

Imunon is led by a team of seasoned professionals with extensive experience in biotechnology and pharmaceutical development. The company’s CEO, Michael H. Tardugno, has been at the helm since 2007, bringing decades of leadership experience in the healthcare sector. Under his guidance, Imunon has made significant strides in advancing its clinical programs and forging strategic partnerships to accelerate its growth.

Core Business Segments

Imunon operates in two primary business segments: immunotherapy and gene-based medicine. These segments are supported by a robust pipeline of products and technologies aimed at addressing unmet medical needs.

Immunotherapy

Imunon’s immunotherapy segment focuses on developing treatments that stimulate the body’s immune system to fight cancer and infectious diseases. The company’s flagship product in this category is ThermoDox®, a heat-activated liposomal formulation of doxorubicin. ThermoDox® is currently being evaluated in clinical trials for the treatment of primary liver cancer and other solid tumors. This innovative therapy leverages heat to release the drug directly at the tumor site, enhancing its efficacy while minimizing systemic side effects.

Gene-Based Medicine

In the gene-based medicine segment, Imunon is pioneering the development of DNA-based therapies that deliver therapeutic genes directly to target cells. The company’s proprietary PLACCINE platform is a key asset in this area, enabling the design of DNA-based vaccines and therapeutics for a wide range of indications. Imunon is actively exploring the potential of this platform to address infectious diseases, including COVID-19, as well as cancer and other chronic conditions.

Business Model

Imunon’s business model is centered on the development and commercialization of innovative therapies that address significant unmet medical needs. The company generates revenue through a combination of licensing agreements, strategic partnerships, and government grants. By leveraging its proprietary technologies and collaborating with leading academic institutions and pharmaceutical companies, Imunon aims to accelerate the development and commercialization of its products.

The company’s approach to integrating products and services is rooted in its commitment to innovation and patient-centric care. Imunon invests heavily in research and development to advance its pipeline and bring new therapies to market. Additionally, the company actively seeks out strategic partnerships to expand its reach and enhance its capabilities.

Strategic Direction

Imunon is focused on advancing its clinical programs and expanding its pipeline to address a broader range of indications. The company’s strategic priorities include:

  • Expanding the PLACCINE Platform: Imunon aims to further develop its PLACCINE platform to create next-generation DNA-based vaccines and therapeutics. The company is particularly interested in exploring applications in oncology and infectious diseases.
  • Advancing Clinical Trials: Imunon is committed to progressing its ongoing clinical trials for ThermoDox® and other pipeline candidates. The company is also exploring opportunities to initiate new trials for additional indications.
  • Sustainability Goals: Imunon is dedicated to incorporating sustainable practices into its operations. The company is exploring ways to reduce its environmental footprint and promote social responsibility.
  • Strategic Partnerships: Imunon plans to continue forging partnerships with academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its products.

Competitive Landscape

Imunon operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Moderna, Inc.: Known for its mRNA-based vaccines, Moderna is a leader in the field of gene-based medicine.
  • BioNTech SE: A pioneer in immunotherapy and mRNA technology, BioNTech is a major player in the oncology and infectious disease markets.
  • Gilead Sciences, Inc.: A global biopharmaceutical company with a strong focus on oncology and antiviral therapies.
  • Novartis AG: A multinational pharmaceutical company with a diverse portfolio of oncology and gene therapy products.

Imunon differentiates itself through its proprietary technologies, such as the PLACCINE platform and ThermoDox®, which offer unique advantages in terms of efficacy and safety.

Risk Factors

Like any biotechnology company, Imunon faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can be time-consuming and costly.
  • Market Dependence: Imunon’s revenue is heavily dependent on the success of its pipeline products. Delays or failures in clinical trials could significantly impact the company’s financial performance.
  • Supply Chain Disruptions: The company relies on a global network of suppliers and manufacturers. Disruptions in the supply chain could delay the production and delivery of its products.
  • Competition: The biotechnology sector is highly competitive, and Imunon faces significant competition from larger, well-established companies.

Recent Developments

Imunon has made several notable advancements in recent years, including:

  • Rebranding to Imunon, Inc.: In 2022, the company rebranded to better reflect its focus on immunotherapy and gene-based medicine.
  • Advancements in the PLACCINE Platform: Imunon has made significant progress in developing its PLACCINE platform, with promising preclinical data for DNA-based vaccines.
  • Clinical Trial Updates: The company has reported positive interim results from its ongoing clinical trials for ThermoDox® in primary liver cancer.
  • Strategic Partnerships: Imunon has entered into collaborations with leading academic institutions to advance its research and development efforts.

Investment Considerations

Investors considering Imunon should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Imunon’s robust pipeline of immunotherapy and gene-based medicine products positions it as a leader in the biotechnology sector.
  • Proprietary Technologies: The company’s PLACCINE platform and ThermoDox® offer unique advantages in terms of efficacy and safety.
  • Experienced Leadership: Imunon is led by a seasoned management team with a proven track record in biotechnology and pharmaceutical development.

Risks

  • Clinical and Regulatory Risks: The success of Imunon’s pipeline is contingent on the outcome of clinical trials and regulatory approvals.
  • Market Competition: The company faces significant competition from larger, well-established players in the biotechnology sector.
  • Financial Uncertainty: As a clinical-stage company, Imunon is not yet profitable and relies on external funding to support its operations.

Conclusion

Imunon, Inc. is a pioneering biotechnology company with a strong focus on immunotherapy and gene-based medicine. With a robust pipeline of innovative products and a commitment to addressing unmet medical needs, Imunon is well-positioned for future growth. However, the company faces several risks, including regulatory challenges and market competition. Investors should carefully consider these factors when evaluating Imunon as a potential investment opportunity.